ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.56
-1.84%
Dow Jones
39,737.26
-1.51%
US Dollar vs MXN
19.1785
0.00%
Brent Oil
77.355
0.00%
Bitcoin
60,689.06
0.03%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. NovaBay Pharmaceuticals Inc New (NBY)

  7. NovaBay Pharmaceuticals Inc New (NBY) Noticias

NBY

NovaBay Pharmaceuticals (NBY)

NovaBay Pharmaceuticals Inc New
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:NBY
FechaHoraFuenteTítuloSímboloCompañía
01/08/202405:50Business WireNovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024AMEX:NBYNovaBay Pharmaceuticals Inc New
30/07/202405:50Business WireNovaBay Pharmaceuticals Reports Record Amazon Prime Day SalesAMEX:NBYNovaBay Pharmaceuticals Inc New
29/07/202415:25Edgar (US Regulatory)Form 8-K - Current reportAMEX:NBYNovaBay Pharmaceuticals Inc New
29/07/202415:05Business WireNovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment OptionAMEX:NBYNovaBay Pharmaceuticals Inc New
26/07/202416:19Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]AMEX:NBYNovaBay Pharmaceuticals Inc New
26/07/202407:30Business WireNovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public OfferingAMEX:NBYNovaBay Pharmaceuticals Inc New
25/07/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:NBYNovaBay Pharmaceuticals Inc New
16/07/202405:50Business WireNovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime DayAMEX:NBYNovaBay Pharmaceuticals Inc New
11/07/202407:50Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesAMEX:NBYNovaBay Pharmaceuticals Inc New
11/07/202405:50Business WireNovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 MillionAMEX:NBYNovaBay Pharmaceuticals Inc New
10/07/202408:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]AMEX:NBYNovaBay Pharmaceuticals Inc New
28/06/202405:50Business WireNovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product PromotionsAMEX:NBYNovaBay Pharmaceuticals Inc New
07/06/202405:50Business WireNovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE AmericanAMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202415:43Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]AMEX:NBYNovaBay Pharmaceuticals Inc New
30/05/202420:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NBYNovaBay Pharmaceuticals Inc New
29/05/202416:22Business WireNovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate UpdatesAMEX:NBYNovaBay Pharmaceuticals Inc New
13/05/202407:30Business WireNovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye SymptomsAMEX:NBYNovaBay Pharmaceuticals Inc New
09/05/202415:05Business WireNovaBay Pharmaceuticals Reports First Quarter 2024 Financial ResultsAMEX:NBYNovaBay Pharmaceuticals Inc New
07/05/202407:00Business WireNovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through AmazonAMEX:NBYNovaBay Pharmaceuticals Inc New
03/05/202405:50Business WireNovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024AMEX:NBYNovaBay Pharmaceuticals Inc New
22/04/202405:57Business WireNovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova SalesAMEX:NBYNovaBay Pharmaceuticals Inc New
19/04/202417:00Business WireNovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder EquityAMEX:NBYNovaBay Pharmaceuticals Inc New
17/04/202405:59Business WireNovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing ExpensesAMEX:NBYNovaBay Pharmaceuticals Inc New
26/03/202415:05Business WireNovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial ResultsAMEX:NBYNovaBay Pharmaceuticals Inc New
25/03/202417:38Business WireNovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024AMEX:NBYNovaBay Pharmaceuticals Inc New
14/03/202407:00Business WireNovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023AMEX:NBYNovaBay Pharmaceuticals Inc New
14/02/202413:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:NBYNovaBay Pharmaceuticals Inc New
30/01/202408:00Business WireNovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based SalesAMEX:NBYNovaBay Pharmaceuticals Inc New
09/01/202408:15Business WireNovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor NetworkAMEX:NBYNovaBay Pharmaceuticals Inc New
04/01/202410:50Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:NBYNovaBay Pharmaceuticals Inc New
 Showing the most relevant articles for your search:AMEX:NBY

Su Consulta Reciente

AMEX
XLE
Energy Select Sector SPDR
NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
MSFT
Microsoft
FX
EURUSD
Euro vs US Dollar
AMEX
XLF
Financial Select Sector
NYSE
MRK
Merck
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
NYSE
BAC
Bank of America
AMEX
SPY
SPDR S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados